

Non Alcoholic Steato-Hepatitis Chronic Kidney Disease

**A study of a new medicine (fazpilodemab) in people with a type of liver disease called non-alcoholic steatohepatitis or NASH**

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis

**Trial Status**  
Terminated

**Trial Runs In**  
5 Countries

**Trial Identifier**  
NCT04171765 GC41033

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

This study will evaluate the efficacy, safety, and pharmacokinetics of BFKB8488A compared to placebo in participants with non-alcoholic steatohepatitis (NASH).

<b>Genentech, Inc. (A part of F. Hoffmann-La Roche Ltd., Switzerland)</b>	<b>Phase 2</b>
Sponsor	Phase

**NCT04171765 GC41033**  
Trial Identifiers

***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥18 Years & ≤ 75 Years

**Healthy Volunteers**  
No